

MOL #59915

Mechanisms underlying activation of soluble guanylate cyclase by the HNO donor Angeli's Salt *

Andreas Zeller, M. Verena Wenzl, Matteo Beretta, Heike Stessel, Michael
Russwurm, Doris Koesling, Kurt Schmidt and Bernd Mayer

Department of Pharmacology and Toxicology, Karl-Franzens-Universität Graz,
A-8010 Graz, Austria (A.Z., M.V.W., M.B., H.S., K.S., B.M.)

Department of Pharmacology and Toxicology, Ruhr-Universität Bochum, D-44780
Bochum, Germany (M.R., D.K.)

MOL #59915

Running Title: Effects of Angeli's salt on soluble guanylate cyclase

Address Correspondence to:

Dr. Bernd Mayer

Department of Pharmacology and Toxicology

Karl-Franzens-Universität Graz

Universitätsplatz 2, A-8010 Graz, Austria

Tel.: +43-316-380-5567

Fax: +43-316-380-9890

e-mail: mayer@uni-graz.at

Number of text pages: 28

Number of tables: 0

Number of figures: 6

Number of references: 40

Number of words in

Abstract: 233

Introduction: 737

Discussion: 1,488

¹Abbreviations: AS, Angeli's salt ($\text{Na}_2\text{N}_2\text{O}_3$; sodium trioxodinitrate); carboxy-PTIO, 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide; DEA/NO, 2,2-diethyl-1-nitroso-oxyhydrazine (DEA/NONOate); DTPA, diethylene triamine pentaacetic acid; DTT, dithiothreitol; NO, nitric oxide; PAECs, porcine aortic endothelial cells; ODQ, 1H-(1,2,4)oxadiazolo(4,3- α) quinoxaline-1-one; sGC, soluble guanylate cyclase; SIN-1, 3-morpholino sydnonimine; SOD, superoxide dismutase; TEA, triethanolamine.

Abstract

HNO (nitroxyl) may be formed endogenously by uncoupled nitric oxide (NO) synthases, enzymatic reduction of NO or as product of vascular nitroglycerin bioactivation. The established HNO donor Angeli's salt (trioxodinitrate, AS) causes cGMP-dependent vasodilation through activation of soluble guanylate cyclase (sGC). We investigated the mechanisms underlying this effect using purified sGC and cultured endothelial cells. AS (up to 0.1 mM) had no significant effect on sGC activity in the absence of superoxide dismutase (SOD) or dithiothreitol (DTT). In the presence of SOD, AS caused biphasic sGC activation (apparent EC_{50} ~10 nM, maximum at 1 μ M) that was accompanied by formation of NO. DTT (2 mM) inhibited the effects of <10 μ M AS but led to sGC activation and NO release at 0.1 mM AS even without SOD. AS had no effect on ferric sGC, excluding activation of the oxidized enzyme by HNO. The NO scavenger carboxy-PTIO inhibited endothelial cGMP accumulation induced by AS in the presence but not in the absence of SOD (EC_{50} ~50 nM and ~16 μ M, respectively). Carboxy-PTIO (0.1 mM) inhibited the effect of \leq 10 μ M AS in the presence of SOD but caused NO release from 0.1 mM AS in the absence of SOD. These data indicate that AS activates sGC exclusively *via* NO, formed either *via* SOD-catalyzed oxidation of HNO or through a minor AS decomposition pathway that is unmasked in the presence of HNO scavenging thiols.

MOL #59915

Activation of soluble guanylate cyclase (sGC¹) represents an established signaling mechanism downstream of NO synthase activation in a variety of tissues including endothelial cells, platelets and neurons (Friebe and Koesling, 2003). NO binds with high affinity to ferrous heme bound to the β -subunit of sGC resulting in pronounced stimulation of cGMP formation (Griffiths *et al.*, 2003). This effect is blocked in a NO-competitive manner by the sGC inhibitor ODQ which oxidizes sGC-bound heme to the ferric form (Schrammel *et al.*, 1996). Recently drugs have been described that stimulate sGC only in the presence of ODQ, suggesting activation of the ferric enzyme (Evgenov *et al.*, 2006). However, a recent study showed that it is the heme-free form of the enzyme that is activated by these drugs (Roy *et al.*, 2008). Since these compounds cause cGMP-dependent vasodilation, heme-free sGC may be present in blood vessels (Evgenov *et al.*, 2006).

The biology of NO is rendered complex by redox reactions yielding NO-related species with distinct biological properties. A prominent example is the NO congener HNO (nitroxyl) which may be formed endogenously by uncoupled NO synthase or reduction of NO by cytochrome c oxidase, xanthine oxidase or hemoglobin (Paolocci *et al.*, 2007; Irvine *et al.*, 2008). The biologically most relevant chemical reaction of HNO is oxidation of low and high molecular mass thiols to the corresponding disulfides with concomitant formation of hydroxylamine (Paolocci *et al.*, 2007). Thus, thiols are useful tools to discriminate between NO and HNO in bioassays (Pino and Feelisch, 1994) and HNO modifies the function of proteins by reaction with essential cysteine residues (Shen and English, 2005). The positive inotropic effect of HNO, for instance, is mediated by sulfhydryl modification of various proteins regulating Ca²⁺ homeostasis in cardiomyocytes (Paolocci *et al.*, 2007). Other examples are glyceraldehyde-3-phosphate dehydrogenase (Lopez *et al.*, 2007) and mitochondrial aldehyde dehydrogenase (DeMaster *et al.*, 1998) which are irreversibly inhibited by HNO-triggered cysteine modification.

While these effects of HNO are cGMP-independent, large body of evidence indicates that HNO released from AS causes vasodilation through stimulation of sGC (Irvine *et al.*, 2008). In line with a report showing that NO is the sole nitrogen monoxide redox form that activates sGC (Dierks and Burstyn, 1996), vasodilation by AS has been attributed to oxidation of HNO to NO by SOD (Murphy and Sies, 1991; Liochev and Fridovich, 2002) or other cellular pathways (Paolocci *et al.*, 2007; Irvine *et al.*, 2008). The effect of SOD has raised considerable confusion because of the difficulties to decide whether SOD-induced increases of NO bioavailability are due to scavenging of superoxide or oxidation of HNO to NO. Thus, while we interpreted the SOD dependence of NO formation by neuronal NO synthase as evidence for enzymatic co-generation of NO and superoxide (Mayer *et al.*, 1995), others claimed that the initial enzymatic product is HNO that is oxidized to NO by SOD (Schmidt *et al.*, 1996). Another example is bioconversion of nitroglycerin by mitochondrial aldehyde dehydrogenase that results in substantial formation of NO in the presence but not in the absence of SOD (Beretta *et al.*, 2008). Again, it remained unclear whether the effect of SOD reflected co-generation of superoxide or oxidation of HNO, a putative product of vascular nitroglycerin metabolism (Booth *et al.*, 2000). While the case of NO synthase was later decided in favor of the superoxide hypothesis (Riethmüller *et al.*, 1999), this issue is still unresolved in the case of nitroglycerin bioactivation.

Contrasting the general view that AS-induced activation of sGC results from oxidation of HNO to NO (Zamora *et al.*, 1995), several studies reported that vasodilation in response to AS was blocked by ODQ but not by the NO scavenger carboxy-PTIO, though the effects of NO donor compounds or endothelial NO synthase activation were inhibited as expected (Li *et al.*, 1999; Costa *et al.*, 2001; Wanstall *et al.*, 2001; Irvine *et al.*, 2003; Irvine *et al.*, 2007). This discrepancy is still unresolved and taken as evidence for NO-independent sGC activation by HNO (Irvine *et al.*, 2008). Similarly, the lack of effect of carboxy-PTIO on AS-induced neuronal cell death led to exclusion of NO as mediator of AS toxicity (Hewett *et al.*, 2005). The present study

MOL #59915

was designed to clarify the mechanisms underlying sGC activation by AS. In particular, we investigated the role of SOD and thiols, the possible activation of ferric sGC by AS-derived HNO and the puzzling lack of effect of carboxy-PTIO on AS-induced vascular cGMP accumulation reported previously.

Materials and Methods

Materials

Bovine lung sGC was purified as described (Russwurm and Koesling, 2005). [α - 32 P]GTP (400 Ci/mmol; NEN Radiochemicals) was from PerkinElmer (Vienna, Austria). AS was from Cayman Europe (Tallin, Estonia). DEA/NO, SIN-1 and ODQ were from Alexis Corporation (Lausen, Switzerland) and purchased *via* Eubio (Vienna, Austria). DEA/NO and AS were dissolved and diluted in 10 mM NaOH. All other chemicals were from Sigma (Vienna, Austria).

Determination of cGMP in cultured PAECs

Porcine aortic endothelial cells were isolated as described previously (Schmidt *et al.*, 1989) and cultured at 37 °C, 5 % CO₂, for up to three passages in Dulbecco's modified Eagle's medium, containing 10 % (v/v) heat-inactivated fetal calf serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 1.25 μ g/ml amphotericin B. For determination of intracellular cGMP accumulation, endothelial cells were grown in 24-well plates, washed and preincubated for 15 min at 37 °C in 50 mM Tris buffer, pH 7.4, containing 100 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 2.5 mM CaCl₂, 1 mM 3-isobutyl-1-methylxanthine, 1 μ M indomethacin, and where indicated 1,000 U/ml SOD, 0.1 mM carboxy-PTIO or 0.1 mM ODQ. Reactions were started by addition of the compounds to be tested and terminated after 2 min by removal of the incubation medium and addition of 0.01 N HCl. Within 1 h, intracellular cGMP was completely released into the supernatant and measured by radioimmunoassay.

Determination of sGC activity

The sGC preparation used for most experiments in the present study exhibited a specific activity of ~ 20 μ mol cGMP \times min⁻¹ \times mg⁻¹ and was stored at a protein concentration of 0.1 mg/ml. Dilution in the assay resulted in a final DTT concentration of 10 μ M. The purified enzyme (50 ng) was incubated at 37 °C for 10 min in a final

MOL #59915

volume of 0.1 ml in the presence of 50 mM TEA/HCl (pH 7.4), 0.5 mM [α - 32 P]GTP, ~250,000 cpm), 3 mM MgCl₂, 1 mM cGMP, and 0.1 mM DTPA. SOD, DTT, donor compounds and scavengers were present as indicated in the text and figures. To minimize HNO scavenging by endogenously present DTT, some experiments were performed with 740 ng of a more concentrated sGC preparation (7.4 mg/ml; specific activity ~10 μ mol cGMP x min⁻¹ x mg⁻¹) in a total volume of 0.2 ml under otherwise identical conditions, resulting in a final DTT concentration of 1 μ M. Reactions were terminated by addition of 450 μ l zinc acetate (120 mM) and 450 μ l sodium bicarbonate (120 mM), followed by isolation of 32 P-cGMP by chromatography over Al₂O₃ columns. Blank values were determined in the absence of sGC.

Determination of NO release

NO release was measured with a Clark-type electrode (World Precision Instruments, Berlin, Germany), calibrated daily with acidified nitrite as described (Mayer *et al.*, 1995). AS or SIN-1 were incubated in 1 ml of 50 mM TEA (pH 7.4), containing 0.1 mM DTPA, in the absence or presence of SOD and DTT as indicated in the text.

Determination of hydroxylamine formation

AS and DEA/NO (0.1 mM each) were incubated at 37°C for 5 min in 0.2 ml of 50 mM TEA buffer (pH 7.4) containing 0.1 mM DTPA in the absence and presence of 2 mM DTT. Hydroxylamine was measured by light absorbance spectroscopy at 700 nm after condensation with 8-hydroxyquinoline and oxidation to indoxine as described (Arnelle and Stamler, 1995). Calibration curves were established with authentic hydroxylamine in the absence and presence of 2 mM DTT.

Results

Figure 1A shows activation of purified sGC by increasing concentrations of AS. AS had a very minor effect even at the highest concentration tested (0.1 mM) in the absence of SOD and DTT, but caused pronounced biphasic sGC activation in the presence of 1,000 U/ml SOD. Note that cGMP formation was slightly stimulated by SOD alone. This effect was sensitive to ODQ and NO scavengers (see Fig. 4 below), suggesting that it reflects stimulation of sGC by airborne NO (Friebe *et al.*, 1996) that is stabilized by SOD. The apparent EC_{50} for the stimulating effect of AS was < 10 nM under these conditions and maximal rates of cGMP formation ($12.7 \pm 0.30 \mu\text{mol} \times \text{min}^{-1} \times \text{mg}^{-1}$) were observed at $1 \mu\text{M}$ of the donor compound. Activation of sGC caused by up to $1 \mu\text{M}$ AS in the presence of SOD was significantly inhibited by DTT, but the effects of high AS concentrations ($\geq 10 \mu\text{M}$) were more pronounced in the presence of DTT, presumably due to triggering SOD-independent sGC activation by AS (Fig. 1, filled circles). As shown in supplemental Fig. S1, cGMP formation induced by $1 \mu\text{M}$ AS in the absence or presence of DTT increased in a roughly linear manner for 8 - 10 min in the presence of SOD.

Determination of NO release yielded similar results. As shown in Fig. 1B, AS ($0.1 \mu\text{M}$ - 0.1 mM) did not release detectable NO (limit ~ 5 nM) upon incubation in buffer alone but a biphasic response was observed in the presence of SOD with maximal NO release, corresponding to a peak concentration of $0.14 \pm 0.008 \mu\text{M}$, occurring at $1 \mu\text{M}$ AS. Under these conditions, the peak concentration of NO released from $1 \mu\text{M}$ DEA/NO was $0.85 \pm 0.01 \mu\text{M}$, indicating that competing reactions preclude quantitative oxidation of AS-derived HNO to NO by SOD. DTT completely prevented the SOD-induced NO release from up to $10 \mu\text{M}$ AS but led to pronounced release of NO from 0.1 mM AS in the absence and presence of SOD (peak concentrations of 0.79 ± 0.023 and $0.50 \pm 0.009 \mu\text{M}$, respectively). Formation of NO was not detectable upon incubation of 0.1 mM nitrite with 2 mM DTT under identical conditions (not shown).

MOL #59915

To illustrate the pattern of NO release, representative traces of NO signals obtained from 1 μ M and 0.1 mM AS in the absence and presence of SOD and DTT are shown in supplemental Fig. S2.

The effect of SOD was most likely due to oxidation of AS-derived HNO to NO, suggesting that inhibition of SOD-induced NO release by DTT reflects scavenging of HNO yielding hydroxylamine. To test this hypothesis, we measured hydroxylamine formation from AS in the absence and presence of DTT in comparison to the NO donor DEA/NO, a structurally related compound with similar half-life. As shown in Fig. 1C, incubation of 0.1 mM AS in the absence and presence of 2 mM DTT led to formation of 6.42 ± 1.28 and 50.3 ± 5.86 μ M hydroxylamine, showing that HNO released from AS is efficiently scavenged by DTT. Hydroxylamine formation from 0.1 mM DEA/NO was 6.85 ± 0.50 μ M in the presence of 2 mM DTT but not detectable (limit ~ 0.5 μ M) in the absence of the thiol, confirming that HNO release is a minor pathway of DEA/NO decomposition at physiological pH.

It was of interest to see whether differences in the SOD concentration-response would allow to distinguish the two major effects of SOD on NO bioavailability, i.e prevention of peroxynitrite formation under conditions of NO/superoxide co-generation and oxidation of HNO to NO. For this purpose we studied the effects of increasing SOD concentrations on purified sGC stimulated with fixed concentrations of either the HNO donor AS (1 μ M) or the NO/superoxide donor SIN-1 (0.1 mM). As shown in Fig. 2A, the rates of cGMP formation induced by AS and SIN-1 were similarly increased by 1 - 1,000 U/ml SOD, indicating that the sGC bioassay does not allow any judgment on the mechanism underlying the effect of SOD. Determination of NO release from AS and SIN-1 (Fig. 2B) yielded seemingly discrepant results, as up to 10 U/ml SOD, which led to more than half-maximal sGC stimulation, caused hardly detectable NO release from both donors. However, despite being very close to the detection limit of the electrode, the NO signals obtained from AS and SIN-1 in the

presence of 10 U/ml SOD allowed to roughly estimate NO peak concentrations of around 3 nM what would be sufficient for significant sGC activation based on a NO binding affinity of about 1 nM (Griffiths *et al.*, 2003). In any case, these results highlight the potential pitfalls of comparing the biological activity of NO with quantitative analysis of NO formation.

Since HNO triggers reductive nitrosylation of ferric heme resulting in formation of ferrous nitrosyl-heme complexes, we tested whether HNO activates oxidized sGC. For this purpose we incubated the purified enzyme with 0.1 μ M AS, a concentration that corresponds to an almost maximally active concentration of the related compound DEA/NO, in the presence of ODQ (0.1 mM) to oxidize sGC-bound heme. As shown in Fig. 3A, AS had no effect on the rates of cGMP formation measured in the absence of SOD with and without ODQ, and the effect of SOD was completely inhibited by ODQ, as expected for NO-mediated sGC activation. To test for a low affinity effect of AS and to minimize HNO scavenging by DTT present endogenously in the sGC preparations, these experiments were repeated with a more concentrated enzyme preparation (final DTT concentration \sim 1 μ M) and a 1,000-fold higher AS concentration (0.1 mM). However, ODQ did not cause significant sGC activation by AS in the absence of SOD under these conditions (not shown). In the presence of SOD, the degree of inhibition by ODQ decreased with increasing AS concentrations (Fig. 3B and 3C), indicating that the effect of ODQ is attenuated under these conditions by AS-derived NO. This observation agrees well with a previous report on NO-competitive sGC inhibition by ODQ (Schrammel *et al.*, 1996) that was confirmed by repeating the experiment shown in Fig. 3B with DEA/NO instead of AS. A plot of ODQ-resistant sGC activity as a function of DEA/NO concentration is shown in supplemental Fig. 3S.

Figure 4A shows the effects of the NO scavengers carboxy-PTIO and hydroxycobalamine (0.1 mM each) on sGC in the absence and presence of DEA/NO (1 μ M),

MOL #59915

AS (1 μ M) and SIN-1 (100 μ M) in the presence of 1,000 U/ml SOD. As expected, sGC activation by the three donor compounds was largely prevented by both scavengers, even though the effect of SIN-1 was significantly less sensitive than that of AS ($p=0.01$). The reason for this difference is unknown. To further elucidate the effects of carboxy-PTIO, we tested the effects of the scavenger on sGC stimulation by increasing concentrations of AS in the absence and presence of SOD. As shown in Fig. 4B, carboxy-PTIO completely inhibited the effect of low AS in the presence of SOD, but the degree of inhibition decreased with increasing AS concentration, hinting at an additional effect of carboxy-PTIO counteracting NO scavenging. This effect became clearly apparent in the absence of SOD. Under these conditions, carboxy-PTIO caused pronounced activation of sGC that was maximal with equimolar AS (0.1 mM), followed by a sharp decline at 1 mM AS. The carboxy-PTIO concentration-response curve shown in Fig. 4C further illustrates the unexpected sGC activation in the presence of equimolar concentrations of AS and carboxy-PTIO. As shown in the inset to Fig. 4C, incubation of AS and carboxy-PTIO (0.1 mM each) gave rise to an electrochemical NO signal corresponding to a peak concentration of 45.9 ± 2.77 nM NO (mean \pm S.E.; $n=3$), indicating that a minor reaction of carboxy-PTIO with either AS or AS-derived HNO results in formation of NO and consequent activation of sGC. Formation of NO was not affected by 1 mM urate (data not shown), presumably excluding NO₂ radical as reactive intermediate.




The biological relevance of our findings was assessed by determination of endothelial cGMP accumulation in response to AS and DEA/NO. Figure 5A shows that DEA/NO caused about 20-fold increases in cGMP levels (from 3.24 ± 0.62 to 70.6 ± 3.7 pmol/ 10^6 cells at 1 μ M DEA/NO) with an EC₅₀ of 0.13 ± 0.013 μ M. SOD caused an about 3-fold left-shift of the DEA/NO concentration-response (EC₅₀ = 0.041 ± 0.015 μ M). Carboxy-PTIO completely inhibited the effects of up to 0.1 μ M DEA/NO and increased the EC₅₀ of the donor 6-fold to 0.81 ± 0.19 μ M. At 1 μ M DEA/NO, carboxy-PTIO inhibited cGMP accumulation by about 30 %, whereas

MOL #59915


inhibition of purified sGC stimulated with the same concentration of the donor was significantly more pronounced (cf. Fig. 4A). This could be a consequence of different exposure periods (2 min in the cell experiments vs. 10 min in the sGC assays) relative to the half-life of DEA/NO. The effects of DEA/NO were completely blocked by 0.1 mM ODQ (data not shown). As shown in Fig. 5B, AS was significantly less potent than DEA/NO in the absence of SOD ($EC_{50} = 16 \pm 2.3 \mu M$), but exhibited similarly high potency in the presence of SOD with an EC_{50} of $0.048 \pm 0.008 \mu M$, corresponding to a 330-fold increase in AS potency by SOD. Carboxy-PTIO (0.1 mM) caused a pronounced 200-fold right-shift of the AS concentration-response curve in the presence of SOD ($EC_{50} = 9.3 \pm 2.2 \mu M$). In contrast, the effect of high AS observed without added SOD was not inhibited by carboxy-PTIO ($EC_{50} = 6.9 \pm 2.1 \mu M$). ODQ completely inhibited the cGMP response to AS both in the absence and in the presence of SOD. Considering the NO-competitive action of ODQ (Schrammel *et al.*, 1996), the more pronounced effect of ODQ on endothelial cGMP accumulation as compared to inhibition of purified sGC (cf. Fig. 3B) indicates that sGC inside the cells is exposed to much lower NO concentrations, possibly due to efficient consumption of NO as described previously (Schmidt and Mayer, 2004).

Discussion

Theoretical chemistry predicts that AS decomposes in aqueous solution *via* reactions [1] and [2] governed by proton concentration, with HNO formation dominating at physiological pH (Dutton *et al.*, 2004).



The fractional contribution of reaction [2] to AS decomposition is difficult to determine experimentally because HNO reacts rapidly ($k = 2 \times 10^9 \text{ M}^{-1} \text{ s}^{-1}$) with NO according to equation [3] (see (Liochev and Fridovich, 2002) and references therein). However, reaction of HNO with thiols according to equation [4] should unmask NO release and allow a rough estimate of the partitioning between reactions [1] and [2].



Accordingly, the significant release of NO from $\geq 10 \mu\text{M}$ AS that we observed in the presence of DTT (Fig. 1B) may reflect thiol-mediated scavenging of HNO and, thus, prevention of NO consumption *via* reaction [3]. Determination of hydroxylamine formation from AS in the presence of DTT suggests 50 % efficiency of reaction [4], but the actual scavenging efficiency of DTT may have been higher because of alternative reactions between HNO and thiols which do not yield hydroxylamine (Paolucci *et al.*, 2007). The amount of NO released from 0.1 mM AS in the presence of DTT was similar to that detected upon decomposition of 1 μM of the related compound DEA/NO (data not shown). Thus, under the assumption that DTT scavenged 50 - 100 % of AS-derived HNO, reaction [2] accounts for 1 - 2 % of AS decomposition at pH 7.4. Prevention of reaction [3] through HNO scavenging

MOL #59915


certainly provides a reliable explanation for SOD-independent activation of purified sGC by AS in the presence of DTT. Considering the high intracellular concentrations of GSH, this pathway may contribute significantly to endothelial cGMP accumulation in response to $\geq 10 \mu\text{M}$ AS (see Fig. 5B).

However, the amount of NO released from AS in the presence of thiols is too small to explain cGMP-mediated vasodilation induced by nanomolar concentrations of AS in some vascular beds (Zamora *et al.*, 1995; Irvine *et al.*, 2003; Favalaro and Kemp-Harper, 2007), hinting at additional mechanisms of sGC activation in tissues. The probably most relevant mechanism is oxidation of HNO to NO by Cu(II), Zn SOD (Murphy and Sies, 1991; Liochev and Fridovich, 2002). The reaction results in formation of Cu(I), Zn SOD which may be re-oxidized slowly to the Cu(II) form by NO, giving rise to formation of $^3\text{NO}^-$ which reacts with O_2 to yield peroxynitrite and eventually nitrate as stable end product (Miranda *et al.*, 2005). In the presence of 1,000 U/ml SOD, corresponding to a SOD concentration of $16 \mu\text{M}$, sGC activation and NO release were both biphasic with maximal efficacy at $1 \mu\text{M}$ AS. Thus, depletion of Cu(II), Zn SOD may explain decreased efficacy of $\geq 10 \mu\text{M}$ AS, although we cannot exclude that high concentrations of AS caused sGC inhibition through modification of essential cysteine residues, as described recently for dinitrosyl-iron complexes (Mayer *et al.*, 2009). Oxidation of HNO most likely explains the more than 300-fold potentiation of AS-induced endothelial cGMP accumulation by SOD. In comparison, SOD only moderately increased the potency of DEA/NO, presumably through scavenging of superoxide generated *via* undefined reactions in the culture medium (see Fig. 5). The present data do not allow judging the relative contribution of HNO oxidation by intracellular SOD vs. thiol-induced NO release to AS-induced cGMP accumulation, but the potency of AS to activate sGC in a given type of tissue is expected to be determined by both SOD and thiol levels. The two pathways mediating sGC activation by AS are schematically illustrated in Fig. 6.

While this manuscript was under review, Jon Fukuto and coworkers reported that AS caused partial activation of purified sGC that was heme-dependent and occurred in

the absence of deliberately added agents known to oxidize HNO to NO. These results led the authors to propose that HNO interacts with sGC-bound heme to activate the enzyme (Miller *et al.*, 2009). The discrepancy between their observation and our data showing hardly any increase in cGMP formation with up to 0.1 mM AS in the absence of SOD (unfilled circles in Fig. 1A) could be due to different experimental conditions (different enzyme preparations, aerobic vs. anaerobic incubation etc.). More importantly, however, without measuring NO it cannot be excluded that sGC was activated by minor amounts of HNO-derived NO formed through some unknown reaction in their assay mixtures. Generation of picomolar concentrations of NO would have been sufficient to explain sGC activation without invoking a direct interaction of HNO with ferrous heme iron.

It was one of the goals of the present study to clarify whether AS causes cGMP accumulation through activation of ferric sGC by HNO according to equation [5].



If this reaction were significant, AS would be expected to stimulate sGC in the presence of the heme oxidant ODQ (Schrammel *et al.*, 1996), as reported for a certain class of sGC activating drugs (Evgenov *et al.*, 2006). However, in the absence of SOD neither low (0.1 μM) nor high (0.1 mM) AS caused significant activation of ODQ-treated sGC, and ODQ completely blocked AS-induced accumulation of cGMP in endothelial cells in the presence and absence of added SOD (see Fig. 5B). At a first glance, the data shown in Fig. 3B might suggest that 10 - 100 μM AS activates ODQ-treated sGC in the presence of SOD. However, replot of the data as ODQ-insensitive sGC activity as a function of AS concentration (see Fig. 3C) revealed that ODQ inhibited cGMP formation in an AS-competitive manner. These results were expectable considering the fact that AS acts *via* NO in the presence of SOD together with NO-competitive sGC inhibition by ODQ (see Fig. S3). A recent

study also reported on lack of activation of ferric sGC by HNO (Miller *et al.*, 2009). This may be explained by a slow reaction of HNO with Fe(III)-sGC as compared to the nearly diffusion-controlled reaction of NO with Fe(II)-sGC (Griffiths *et al.*, 2003). The rate constant of reaction [5] is not known but the rates for reductive nitrosylation of other ferric heme proteins are in the range of $10^4 - 10^5 \text{ M}^{-1} \text{ s}^{-1}$ (Miranda *et al.*, 2003). Our data indicate that the affinity of Fe(III)-sGC for HNO is similarly low, precluding activation of the oxidized enzyme as a relevant mechanism of HNO-induced cGMP accumulation *in vivo*.

Since the first description of NO scavenging by carboxy-PTIO (Akaike *et al.*, 1993) this drug has been used frequently to discriminate between NO-dependent and NO-independent biological processes. However, effects of carboxy-PTIO unrelated to NO scavenging have questioned the usefulness of this drug as selective pharmacological tool (Pfeiffer *et al.*, 1997). Nevertheless, the failure of carboxy-PTIO to inhibit cGMP-mediated vasodilation to AS is still taken as evidence for NO-independent sGC activation by HNO (Irvine *et al.*, 2008). Our results with cultured endothelial cells clearly show that carboxy-PTIO inhibits cGMP accumulation induced by AS in the presence of extracellular SOD, demonstrating that the drug does scavenge AS-derived NO as expected. However, in line with several published studies (Li *et al.*, 1999; Costa *et al.*, 2001; Wanstall *et al.*, 2001; Irvine *et al.*, 2003; Hewett *et al.*, 2005; Irvine *et al.*, 2007), carboxy-PTIO did not block the effect of AS in the absence of added SOD (see Fig. 5B). The different sensitivities of low and high AS to carboxy-PTIO could be explained by a predominant reaction of the drug with NO formed extracellularly by SOD at low concentrations of AS, whereas the effect of high AS (in the absence of SOD) might occur intracellularly and hence be resistant to carboxy-PTIO.

Alternatively, formation of NO in the combined presence of carboxy-PTIO and AS (see Fig. 4) may counteract the NO scavenging effect of the drug. Our observation

MOL #59915

confirms a previous report from Rand and coworkers who suggested that carboxy-PTIO oxidizes HNO to NO (Ellis *et al.*, 2001). The biphasic effect of carboxy-PTIO is hard to explain without knowing the rate constants of the relevant reactions that may take place with AS, HNO and putative reaction intermediates. Presumably, scavenging and/or consumption of NO prevails over NO formation at excess carboxy-PTIO. Considering the manifold unspecific effects of carboxy-PTIO that limit the usefulness of this drug as pharmacological tool, we refrained from further investigating the mechanism underlying carboxy-PTIO-triggered NO release from AS and/or HNO.

Taken together, our data suggest that AS activates sGC exclusively through NO formation. Besides the established oxidation of HNO to NO by Cu(II), Zn SOD, we found that scavenging of HNO by thiols unmasks NO release *via* a minor pathway of AS decomposition that may partially account for AS-induced cGMP accumulation in tissues. Activation of ferric sGC by HNO could be excluded as relevant mechanism of action of AS.

Acknowledgments

We thank Dr. Jon Fukuto (UCLA) for helpful discussion and Margit Rehn for excellent technical assistance.

References

- Akaike T, Yoshida M, Miyamoto Y, Sato K, Kohno M, Sasamoto K, Miyazaki K, Ueda S and Maeda H (1993) Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/NO through a radical reaction. *Biochemistry* **32**:827-832.
- Arnelle DR and Stamler JS (1995) NO⁺, NO, and NO⁻ donation by S-nitrosothiols: Implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation. *Arch Biochem Biophys* **318**:279-285.
- Beretta M, Gruber K, Kollau A, Russwurm M, Koesling D, Goessler W, Keung WM, Schmidt K and Mayer B (2008) Bioactivation of nitroglycerin by purified mitochondrial and cytosolic aldehyde dehydrogenases. *J Biol Chem* **283**: 17873-17880.
- Booth BP, Tabrizi-Fard MA and Fung HL (2000) Calcitonin gene-related peptide-dependent vascular relaxation of rat aorta: An additional mechanism for nitroglycerin. *Biochem Pharmacol* **59**:1603-1609.
- Costa G, Labadía A, Triguero D, Jiménez E and García-Pascual A (2001) Nitroergic relaxation in urethral smooth muscle: Involvement of potassium channels and alternative redox forms of NO. *Naunyn-Schmiedeberg's Arch Pharmacol* **364**:516-523.
- DeMaster EG, Redfern B and Nagasawa HT (1998) Mechanisms of inhibition of aldehyde dehydrogenase by nitroxyl, the active metabolite of the alcohol deterrent agent cyanamide. *Biochem Pharmacol* **55**:2007-2015.
- Dierks EA and Burstyn JN (1996) Nitric oxide (NO center dot), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase. *Biochem Pharmacol* **51**:1593-1600.

MOL #59915

- Dutton AS, Fukuto JM and Houk KN (2004) Mechanisms of HNO and NO production from Angeli's Salt: Density functional and CBS-QB3 theory predictions. *J Am Chem Soc* **126**:3795-3800.
- Ellis A, Lu H, Li CG and Rand MJ (2001) Effects of agents that inactivate free radical NO (NO center dot) on nitroxyl anion-mediated relaxations, and on the detection of NO center dot released from the nitroxyl anion donor Angeli's salt. *Br J Pharmacol* **134**:521-528.
- Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HHHW and Stasch JP (2006) NO-independent stimulators and activators of soluble guanylate cyclase: Discovery and therapeutic potential. *Nat Rev Drug Discov* **5**:755-768.
- Favaloro JL and Kemp-Harper BK (2007) The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature. *Cardiovasc Res* **73**:587-596.
- Friebe A and Koesling D (2003) Regulation of nitric oxide-sensitive soluble guanylyl cyclase. *Circ Res* **93**:96-105.
- Friebe A, Malkewitz J, Schultz G and Koesling D (1996) Positive effects of pollution? *Nature* **382**:120.
- Griffiths C, Wykes V, Bellamy TC and Garthwaite J (2003) A new and simple method for delivering clamped nitric oxide concentrations in the physiological range: application to activation of guanylyl cyclase-coupled nitric oxide receptors. *Mol Pharmacol* **64**:1349-1356.
- Hewett SJ, Espey MG, Ulasz TF and Wink DA (2005) Neurotoxicity of nitroxyl: Insights into HNO and NO biochemical imbalance. *Free Rad Biol Med* **39**:1478-1488.
- Irvine JC, Favaloro JL and Kemp-Harper BK (2003) NO activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries. *Hypertension* **41**:1301-1307.

- Irvine JC, Favalaro JL, Widdop RE and Kemp-Harper BK (2007) Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae. *Hypertension* **49**:885-892.
- Irvine JC, Ritchie RH, Favalaro JL, Andrews KL, Widdop RE and Kemp-Harper BK (2008) Nitroxyl (HNO): the Cinderella of the nitric oxide story. *Trends Pharmacol Sci* **29**:601-608.
- Li CG, Karagiannis J and Rand MJ (1999) Comparison of the redox forms of nitrogen monoxide with the nitrergic transmitter in the rat anococcygeus muscle. *Br J Pharmacol* **127**:826-834.
- Liochev SI and Fridovich I (2002) Nitroxyl (NO⁻): a substrate for superoxide dismutase. *Arch Biochem Biophys* **402**:166-171.
- Lopez BE, Wink DA and Fukuto JM (2007) The inhibition of glyceraldehyde-3-phosphate dehydrogenase by nitroxyl (HNO). *Arch Biochem Biophys* **465**:430-436.
- Mayer B, Klatt P, Werner ER and Schmidt K (1995) Kinetics and mechanism of tetrahydrobiopterin-induced oxidation of nitric oxide. *J Biol Chem* **270**:655-659.
- Mayer B, Kleschyov AL, Stessel H, Russwurm M, Münzel T, Koesling D and Schmidt K (2009) Inactivation of soluble guanylate cyclase by stoichiometric S-nitrosation. *Mol Pharmacol* **75**:886-891.
- Miller TW, Cherney MM, Lee AJ, Francoleon NE, Farmer PJ, King SB, Honbbs AJ, Miranda KM, Burstyn JN and Fukuto J (2009) The effects of nitroxyl (HNO) on soluble guanylate cyclase activity: Interactions at ferrous heme and cysteine thiols. *J Biol Chem*:[June 15, Epub ahead of print].
- Miranda KM, Dutton AS, Ridnour LA, Foreman CA, Ford E, Paolocci N, Katori T, Tocchetti CG, Mancardi D, Thomas DD, Espey MG, Houk KN, Fukuto JM and Wink DA (2005) Mechanism of aerobic decomposition of Angeli's salt (Sodium Trioxodinitrate) at physiological pH. *J Am Chem Soc* **127**:722-731.

MOL #59915

- Miranda KM, Paolocci N, Katori T, Thomas DD, Ford E, Bartberger MD, Espey MG, Kass DA, Feelisch M, Fukuto JM and Wink DA (2003) A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. *Proc Natl Acad Sci USA* **100**:9196-9201.
- Murphy ME and Sies H (1991) Reversible conversion of nitroxyl anion to nitric oxide by superoxide dismutase. *Proc Natl Acad Sci USA* **88**:10860-10864.
- Paolocci N, Jackson MI, Lopez BE, Miranda K, Tocchetti CG, Wink DA, Hobbs AJ and Fukuto JM (2007) The pharmacology of nitroxyl (HNO) and its therapeutic potential: Not just the janus face of NO. *Pharmacol Ther* **113**:442-458.
- Pfeiffer S, Leopold E, Hemmens B, Schmidt K, Werner ER and Mayer B (1997) Interference of carboxy-PTIO with nitric oxide- and peroxynitrite-mediated reactions. *Free Rad Biol Med* **22**:787-794.
- Pino RZ and Feelisch M (1994) Bioassay discrimination between nitric oxide (NO center dot) and nitroxyl (NO-) using L-cysteine. *Biochem Biophys Res Commun* **201**:54-62.
- Riethmüller C, Gorren ACF, Pitters E, Hemmens B, Habisch HJ, Heales SJR, Schmidt K, Werner ER and Mayer B (1999) Activation of neuronal nitric-oxide synthase by the 5-methyl analog of tetrahydrobiopterin - Functional, evidence against reductive oxygen activation by the pterin cofactor. *J Biol Chem* **274**:16047-16051.
- Roy B, Mo E, Vernon J and Garthwaite J (2008) Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. *Br J Pharmacol* **153**:1495-1504.
- Russwurm M and Koesling D (2005) Purification and characterization of NO-sensitive guanylyl cyclase. *Methods Enzymol* **396**:492-501.
- Schmidt HHHW, Hofmann H, Schindler U, Shutenko ZS, Cunningham DD and Feelisch M (1996) No center dot NO from NO synthase. *Proc Natl Acad Sci USA* **93**:14492-14497.

MOL #59915

- Schmidt K and Mayer B (2004) Consumption of nitric oxide by endothelial cells: Evidence for the involvement of a NAD(P)H-, flavin- and heme-dependent dioxygenase reaction. *FEBS Letters* **577**:199-204.
- Schmidt K, Mayer B and Kukovetz WR (1989) Effect of calcium on endothelium-derived relaxing factor formation and cGMP levels in endothelial cells. *Eur J Pharmacol* **170**:157-166.
- Schrammel A, Behrends S, Schmidt K, Koesling D and Mayer B (1996) Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. *Mol Pharmacol* **50**:1-5.
- Shen B and English AM (2005) Mass spectrometric analysis of nitroxyl-mediated protein modification: Comparison of products formed with free and protein-based cysteines. *Biochemistry* **44**:14030-14044.
- Wanstall JC, Jeffery TK, Gambino A, Lovren F and Triggle CR (2001) Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. *Br J Pharmacol* **134**:463-472.
- Zamora R, Grzesiok A, Weber H and Feelisch M (1995) Oxidative release of nitric oxide accounts for guanylyl cyclase stimulating, vasodilator and anti-platelet activity of Piloty's acid: A comparison with Angeli's salt. *Biochem J* **312**:333-339.

MOL #59915

FOOTNOTES

*This work was supported by the Fonds zur Förderung der Wissenschaftlichen
Forschung in Austria [W901 DK Molecular Enzymology and P20669] and the
Deutsche Forschungsgemeinschaft [KO1157/4-1].

Address reprint requests to:

Dr. Bernd Mayer

Department of Pharmacology and Toxicology

Karl-Franzens-Universität Graz

Universitätsplatz 2, A-8010 Graz, Austria

Tel.: +43-316-380-5567

Fax: +43-316-380-9890

e-mail: mayer@uni-graz.at

Legends for figures

Fig. 1. Effects of AS on activation of purified sGC (A), release of NO (B) and hydroxylamin formation (C).

A: Purified bovine lung sGC (50 ng) was incubated at 37 °C for 10 min in a final volume of 0.1 ml with increasing concentrations of AS in the presence of 50 mM TEA/HCl (pH 7.4), 0.5 mM [α - 32 P]GTP, ~250,000 cpm), 3 mM MgCl₂, 1 mM cGMP, and 0.1 mM DTPA. SOD (1,000 U/ml) and DTT (2 mM) were present as indicated. Formation of 32 P-cGMP was determined as described in Materials and Methods. Data are mean values \pm S.E. of three experiments. B: AS was incubated at the indicated concentrations in 1 ml of TEA buffer (pH 7.4), containing 0.1 mM DTPA, in the absence and presence of SOD and DTT as indicated, and NO formation measured with a Clark-type electrode. Data are expressed as mean NO peak concentration \pm S.E. of three experiments. C: AS and DEA/NO (0.1 mM each) were incubated at 37°C for 5 min in 0.2 ml of 50 mM TEA buffer (pH 7.4) containing 0.1 mM DTPA in the absence and presence of 2 mM DTT. Hydroxylamine was measured by light absorbance spectroscopy at 700 nm after condensation with 8-hydroxyquinoline and oxidation to indooxine. Data are mean values \pm S.E. of three experiments. n.d., not detectable.

Fig. 2. Effects of SOD concentration on activation of purified sGC (A) and release of NO (B).

Activation of sGC (A) and formation of NO (B) were determined in the presence of 1 μ M AS or 100 μ M SIN-1 and the indicated concentrations of SOD as described in the legend to Fig. 1. Data are mean values \pm S.E. of three experiments.

MOL #59915

Fig. 3. Effect of ODQ on activation of purified sGC by AS.

A: Purified sGC (50 ng) was incubated as described in the legend to Fig. 1 with 0.1 μ M AS in the absence and presence of ODQ (0.1 mM) and SOD (1,000 U/ml). B: Purified sGC (740 ng) was incubated in 0.2 ml with increasing concentrations of AS in the presence of SOD (1,000 U/ml) with and without 0.1 mM ODQ. Other experimental conditions were as described in the legend to Fig. 1. Data are mean values \pm S.E. of three experiments. C: Mean values of sGC activity measured in the absence and presence of ODQ (shown in panel B) were taken to plot the fraction of residual sGC activity in the presence of ODQ as a function of AS concentration.

Fig. 4. Effects of carboxy-PTIO and hydroxy-cobalamine on AS-induced activation of purified sGC.

Purified sGC (50 ng) was incubated as described in the legend to Fig. 1. A: Effects of carboxy-PTIO and hydroxy-cobalamine (0.1 mM each) on sGC activity measured in the presence of SOD (1,000 U/ml) and DEA/NO (1 μ M), AS (1 μ M) or SIN-1 (100 μ M). B: Effects of AS concentration on sGC activity in the presence of carboxy-PTIO with and without SOD (1,000 U/ml). The data on enzyme activity measured in the absence of carboxy-PTIO taken from Fig. 1A are included for better comparison. C: Effects of increasing carboxy-PTIO concentrations on sGC activity measured in the presence of 0.1 mM AS in the absence of SOD. Data are mean values \pm S.E. of three experiments. Inset to panel C: Representative trace of NO formation in the presence of AS and carboxy-PTIO (0.1 mM each; n=3).

OH-cobalamine, hydroxy-cobalamine, cPTIO, carboxy-PTIO.

MOL #59915

Fig. 5. Effects of DEA/NO (A) and AS (B) on cGMP accumulation in cultured PAECs.

Porcine aortic endothelial cells were grown in 24-well plates, washed and preincubated for 15 min at 37 °C in 50 mM Tris buffer, pH 7.4, containing 100 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 2.5 mM CaCl₂, 1 mM 3-isobutyl-1-methylxanthine, 1 µM indomethacin, and where indicated 1,000 U/ml SOD, 0.1 mM carboxy-PTIO or 0.1 mM ODQ. The cells were then incubated for 2 min with the indicated concentrations of DEA/NO (A) or AS (B), followed by determination of intracellular cGMP as described in Materials and Methods. Data are mean values ± S.E. of three independent experiments. cPTIO, carboxy-PTIO.

Fig. 6. Schematic illustration of AS decomposition pathways leading to sGC activation.

At physiological pH, the predominant pathway of AS decomposition yields HNO, which is oxidized to NO by Cu(II), Zn SOD and possibly other physiological oxidants. NO formed *via* an alternative decomposition pathway, which predominates at acidic pH (Dutton *et al.*, 2004), is efficiently scavenged by the excess of AS-derived HNO, preventing NO-mediated activation of sGC in the absence of SOD and thiols (RSH). HNO reacts rapidly with low molecular mass thiols (DTT in the present study) yielding hydroxylamine (NH₂OH) and the corresponding disulfides. At millimolar RSH concentrations, this reaction outcompetes oxidation of HNO to NO by SOD as well as HNO-mediated NO scavenging (thereby unmasking NO release from AS). Reaction of HNO with protein sulfhydryls may result in formation of the corresponding N-hydroxysulfonamide derivatives (RS(O)NH₂) and consequent irreversible changes in the function of specific HNO target proteins (see Paolocci *et al.*, 2007).






Fig. 1





Fig. 2




Fig. 3






Fig. 4





Fig. 5

Fig. 6

